Purpose Clinicopathologic features and biochemical recurrence are sensitive, but not
specific, predictors of metastatic disease and lethal prostate cancer. We hypothesize that a …

BACKGROUND Gene expression profiling of prostate carcinoma offers an alternative means
to distinguish aggressive tumor biology and may improve the accuracy of outcome …

Purpose: Patients with locally advanced prostate cancer after radical prostatectomy are
candidates for secondary therapy. However, this higher risk population is heterogeneous …

One of the major problems in management of prostate cancer is the lack of reliable genetic
markers predicting the clinical course of the disease. We analyzed expression profiles of …

Background: Due to their varied outcomes, men with biochemical recurrence (BCR)
following radical prostatectomy (RP) present a management dilemma. Here, we evaluate …

Predicting prognosis in prostate carcinoma remains a challenge when using clinical and
pathologic criteria only. We used an array-based DASL® assay to identify molecular …

Background Prostate cancer patients who have a detectable prostate-specific antigen (PSA)
postprostatectomy may harbor pre-existing metastatic disease. To our knowledge, none of …

The critical clinical question in prostate cancer research is: How do we develop means of
distinguishing aggressive disease from indolent disease? Using a combination of proteomic …

Background Surgery is a standard first-line therapy for men with intermediate-or high-risk
prostate cancer. Clinical factors such as tumor grade, stage, and prostate-specific antigen …

Importance Decipher (Decipher Biosciences Inc) is a genomic classifier (GC) developed to
estimate the risk of distant metastasis (DM) after radical prostatectomy (RP) in patients with …